Downward Revision To 2012 Drug Market OutlookJuly 2012 | Industry Trend Analysis
BMI View: Despite a downgrade to our 2012 growth projections for Poland's pharmaceutical market and a less bullish long-term view on the zloty against the US dollar and euro, we continue to have a positive view of the Polish drug market. Despite the short-term challenges the market remains attractive over the medium term, as one of Central Europe's larger markets the combination of positive demographics and economic growth will be a driver of growth. Over a longer time period, the government's aggressive downward pressure on drug reimbursement expenditure will be reduced despite continued measures to decrease spending in the medium term.
To read the full article, please choose one of the following options: